Clinical trial
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
NCT01620190 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
- Lead sponsor
- University of Washington
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 2, 2012
- Completion date
- April 29, 2019
- Enrollment
- 26 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer